Teva to Acquire Emalex for $900M, Securing Phase III Tourette’s Therapy
TEVA•Teva will pay $700m upfront plus $200m in potential milestones to acquire neuroscience specialist Emalex, gaining ecopipam, a Phase III pediatric Tourette’s therapy. Ecopipam aims for US approval filing in H2 2026 with orphan drug designation and could become the first new Tourette’s treatment in over a decade.
1. Deal Terms and Pipeline Addition
Teva agreed to acquire Emalex for $700m upfront and up to $200m in milestones, integrating the company’s neurology-focused pipeline. The deal secures ecopipam, a first-in-class D1 receptor therapy that has already achieved a Phase III win in pediatric Tourette’s.
2. Ecopipam’s Clinical and Market Potential
Ecopipam holds orphan drug designation and is scheduled for a US approval filing in H2 2026, targeting market entry by early 2027. Analysts project it could generate up to $1 billion in peak US sales by 2035, positioned in refractory settings with stronger pricing power.
3. Strategic Growth and Financial Outlook
Teva’s innovative medicines portfolio grew 41% year-over-year in Q1 2026, providing the flexibility to pursue targeted acquisitions without immediate patent cliff pressures. Executives emphasize a precise dealmaking approach to bolster neuroscience assets and drive long-term margin expansion.
